Lab Notes Newsletter
Welcome to the June edition of our newsletter!
For 40 years, we’ve helped scientists harness the full potential of biology with next-generation technology. Here we share the latest in automated, end-to-end solutions that span research disciplines to advance scientific discovery and improve the quality of human life worldwide.
Nobel Laureate Professor Sir Martin Evans opens Molecular Devices’ Cardiff facility to manufacture patient-derived organoids for research and drug discovery
Molecular Devices is the world’s only company offering a service to manufacture standardized, quality-tested patient-derived organoids at a scale of many millions per batch
On June 5, 2024, Molecular Devices, LLC. officially opened its custom-built site in Cardiff, UK. The multi-million-pound facility was custom-built for the company’s proprietary bioprocess workflow and unique bioreactor technology that enables the quality-controlled manufacturing of patient-derived organoids (PDOs) at scale. High volumes of 3D Ready? reproducible PDOs are offered as a bespoke service and cryopreserved in an assay-ready format. These can be thawed, plated, and used as desired by researchers.
Life Sciences Plant Will Support Global Drug Development
Molecular Devices is the only company to offer a service to manufacture organoids, at a scale of many millions per batch, in an industrial environment.
Business News Wales spoke to Victoria Marsh-Durban, director of custom organoid services and site lead for the new facility, about the academic and industrial collaboration which brought about such a ground-breaking development.
Women in Stem with Vicky Marsh Durban
In this article, Drug Target Review features Dr. Vicky Marsh Durban, Director of Custom Organoid Services at Molecular Devices, as part of their Women in Stem series.
Check out the eQ&A for more on her journey, what inspired her to pursue a career in the sciences, and the challenges she overcame along the way.
Organoids Stand Out as Stand Ins in Drug Development
This article explores the evolving landscape of organoid technology and its transformative impact on drug development. Featuring industry voices from Corning Life Sciences, Charles River Laboratories, and Emulate, the story also highlights how Molecular Devices is tackling large-scale production with a focus on scalability, reproducibility, and genetic diversity.
Ensure sterility with QPix Microbial Colony Pickers?
Are you looking to enhance sterility in your laboratory and prevent the risk of cross-contamination? Discover how the QPix? Microbial Colony Picker can transform your lab operations with our latest application note,?QPix Microbial Colony Pickers ensure sterility by preventing the risk of cross-contamination.
The importance of microplate readers in 3D Biology?
The arrival of 3D biology represents a paradigm shift in disease modeling and drug development. Traditional in vitro 2D plate-based cell models are being replaced by 3D cell model organoid systems which better represent in vivo physiological traits and biological processes of native tissue. Organoids provide cell and tissue-type insight that aims to accelerate the pace of disease research and drug screening.
Microplate readers play a critical role in 3D biology workflows. This new LabX article explores a recent study titled “A walkaway solution for assessing drug effects in patient-derived colorectal cancer organoids” describing the use of the SpectraMax? iD5 Multi-Mode microplate reader in cancer organoid cell viability assays.
Master GxP Compliance: Essential Guide Available Now!
Staying on top of GxP compliance is crucial in the regulated laboratory environment. Simplify your approach with our new infographic, "5 Essential Factors for GxP Compliance in a Regulated Laboratory."
Key insights you'll gain:
Ready to enhance your lab’s compliance??Download the infographic now.
Can Organoids Unlock the Pathology of Traumatic Brain Injuries
About five million people in the United States alone live with traumatic brain injuries (TBIs). These injuries can quadruple the risk of developing Alzheimer’s disease, and other dementia types, and increase the likelihood of developing neurodegenerative diseases such as amyotrophic lateral sclerosis. Rodent models of TBI have clarified some aspects of these injuries, however, most treatment approaches have had limited success because some of the details of the underlying mechanisms are still unclear.
Watch the new on-demand GEN webinar featuring Justin Ichida, PhD, an expert in stem cell biology and regenerative medicine at the Keck School of Medicine at the University of Southern California. Dr. Ichida discusses how he used organoids to understand the causes of neuronal damage following TBIs and ways of mitigating injury risks. He also presents results from a study that used lab-grown human brain organoid models to parse the genetic mechanisms involved in TBIs and explores their connection to neurodegenerative disorders.
EVENTS
June 10 - 14, 2024 | Seattle, WA
June 25 - 29, 2024 | Vienna, Austria?
July 10 - 13, 2024 | Hamburg, Germany